Duda's group is focused on studies of tumor interaction with its microenvironment, with the goal of identifying the cellular and molecular mechanisms of: 1 local tumor progression in liver cancers and metastatic tumor progression in other gastrointestinal cancers and in prostate and breast malignanciesand 2 treatment resistance in advanced cancers. The ultimate goal is to identify and validate targets for combination therapy with radiation and immunotherapy in preclinical studies, and in parallel conduct studies of biomarkers of response in correlative clinical studies.
He has been invited to present his results at over local, national and international meetings, including Grand Rounds, Plenary Talks and Keynote Lectures.
Accepted Apr Copyright © The Authors.
For his work, Dr. After graduation, he pursued postdoctoral training with Professor Rakesh K. For more information, see full CV at: steele.
Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma. Clin Cancer Res A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients cancer de piele la barbati brain metastases.
Breast Cancer Res Treat Clin Transl Radiat Oncol ; Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med Hepatology Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer PEACE : A study protocol.
Endosc Ultrasound JAMA Oncol Cancer Res ; FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer NPJ Breast Cancer ; Probing tumor neuroendocrine cancer prognosis liver in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
MATERIALS AND METHODS: Imaging studies of 22 patients 12 men, mean age 60 years with histopathologically confirmed diagnosis, evaluated in the authors's institution during the last five years were retrospectively reviewed by two radiologists, with findings being consensually described focusing on changes observed at computed tomography. Only one typical carcinoid presented the characteristic appearance of central endobronchial nodule with distal pulmonary atelectasis, while the others were pulmonary nodules or masses. Neuroendocrine cancer prognosis liver atypical carcinoids corresponded to peripheral heterogeneous masses. One out of the three LCNCs was a peripheral homogeneous mass, while the others were ill-defined and heterogeneous. The 11 SCLCs corresponded to central, infiltrating and heterogeneous masses with secondary pleuropulmonary changes.
Sci Rep ; Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma. Sci Transl Med Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.
NPJ Precis Oncol ; Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
Theranostics ; Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.
United European Gastroenterol J ; Neuroendocrine cancer prognosis liver cerebellar window for intravital imaging of normal and disease states in mice.
Nat Protoc ;